hOMSC 200
Alternative Names: Allogeneic human oral mucosal stem cells- CYTORA; hoMSC-200Latest Information Update: 25 Aug 2023
Price :
$50 *
At a glance
- Originator CYTORA
- Class Foot disorder therapies; Skin disorder therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Diabetic foot ulcer
Most Recent Events
- 25 Aug 2023 Cytora has patent protection for hOMSC technology platform worldwide (Cytora website, August 2023)
- 06 Jan 2022 Phase-I/II clinical trials in Diabetic foot ulcer in Israel (parenteral) (NCT06003530)